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OBJECTIVES: To evaluate the cost of anemia management according to hemoglo-
bin level variability in hemodialysis (HD) patients.METHODS:Thiswas a retrospec-
tive study based on computerized medical files, (Hemodial® software database),
which included 636 HD patients in 5 dialysis centers in 2009. Patients were evalu-
able if they were regularly hemodialyzed, had at least one Hb recorded per month
and were monitored for at least 4 months. “Annual Hb values” were categorized
according to theirmonthlymeanHb (Ideal [10Hb 12 g/dL; n119]; High [Hb12
g/dL; n61] and Low [Hb  10 g/dL; n18] if 75% of time in respective category,
otherwise categorized in Fluctuating; n438). RESULTS: Out of 636 evaluable pa-
tients (mean age, 67 y; male, 59.4%) underwent 144 HD sessions (median); 16.8%
were new dialysis patients. The cost of anemiamanagement wasmainly related to
erythropoiesis-stimulating agents (68% of total cost for Low category and approx-
imately 90% for other categories). Adjusted predictive factors for higher costs of
anemia management (p0.0001) were: dialysis center (from 2518 to 5617€), age
(4911€  55 y vs. 5378€ 65–75 y), female gender (4911€ vs. 4398€ for male), serum
ferritin (5102€ for 200–500 g/mL vs. 4646€ for 500 g/mL) and dialysis vintage
(4911€ if  2 y vs. 2952€ if 4–6 y). The cost for patients in the Low Hb category (13
005€) was significantly higher compared to the others categories: Ideal (5034€),
Fluctuating (4911€) and High (2418€). CONCLUSIONS: Predictive of higher costs of
anemiamanagement in HD patients were the dialysis center, Low Hb category and
patients starting dialysis. Different treatment strategies led to acceptable Hb levels
but showed substantially different costs.
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OBJECTIVES: According to 2009 figures from the US Renal Data System, 17% of all
patients received their first dialysis with private insurance coverage. Ferric citrate
(FC) is a phosphate binder (PB) in clinical development for the treatment of hyper-
phosphatemia in ESRD patients. Patients receiving FC in clinical studies experi-
enced reductions in serum phosphorus, and increases in serum ferritin and satu-
rated transferrin (TSAT). In an observational study analyzing data of a large dialysis
provider, similar increases in ferritin and TSAT in patients with stable hemoglobin
were associated with reduced doses of intravenous (IV) iron and erythropoiesis-
stimulating agents (ESAs) such as epoetin alfa. Reduced IV iron and ESA use could
lower costs of ESRD treatment for insurers.METHODS:We created amanaged care
cost-offset model that considered annual treatment costs of ESRD patients pre-
scribed FC versus alternative PBs. The model assumed similar efficacy and cost
neutrality between FC and other PBs. Baseline input values were derived from
published sources as well as a database analysis from a large US dialysis provider.
Monte Carlo simulations were performed using varying model inputs such as the
number of patients insured, proportion of ESRD patients on PBs, number of dialysis
sessions, estimated cost for dialysis, and ESA and iron costs from observed dose
ranges. RESULTS: Results of the simulation were used to derive a 90% confidence
interval for the potential annual cost savings realized with FC use. Simulations
show a 90% probability that an insurer serving 500 dialysis patients could save
between $389,000 and $829,000 annually with the use of FC. The model was most
sensitive to the number of dialysis sessions per month, health plan size, ESA cost,
and proportion of ESRD patients receiving PBs. CONCLUSIONS: The use of FC over
alternative PBs could create a meaningful cost-offset savings and help reduce the
economic burden of treating patients with ESRD.
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OBJECTIVES: The United States Renal Data System reported that of $2.78 billion
spent on injectable drugs for patients with end-stage renal disease (ESRD) during
2009, $1.89 billion was for erythropoiesis-stimulating agents (ESAs), such as epo-
etin alfa. These costs were reimbursed to dialysis providers under the Medicare
Prospective Payment System, where dialysis payment is bundled with injectable
drugs payment. Oral ferric citrate (FC) is a phosphate binder in clinical develop-
ment for hyperphosphatemia treatment in ESRD patients. Clinical trials demon-
strated that FC lowers patients’ serum phosphorus levels with the added benefit of
increasing patients’ serum ferritin and saturated transferrin (TSAT) levels. In an
observational study analyzing data of a large dialysis provider, similar increases in
ferritin and TSAT in patientswith stable hemoglobinwere associatedwith reduced
doses of intravenous (IV) iron and ESAs. METHODS: We created a facility-level
Medicare cost-offset model that considered annual costs of ESRD treatment for
patients prescribed FC versus other phosphate binder medications (PBs). The
model assumed equal price and efficacy between FC and competitor PBs. Model
inputs included the Medicare average sales price of iron and ESAs, proportion of
ESRD patients on PBs, facility-level cost, and Medicare reimbursement rates with
case-mix adjusters. Margin was calculated as the difference between reimburse-
ment and cost.We assessed the effects of FC use to dialysis providers by comparing
margin for patients on FC versus those taking other PBs. RESULTS: With FC use
versus other PBs, annual facility-level reductions in ESA and IV iron administration
were 9.60% and 11.9%, respectively. These decreases translated to an annual cost
savings of approximately 2.56% of the facility’s total annual bundled Medicare
reimbursement. CONCLUSIONS: A 2% potential cost savings with FC use in pa-
tients taking PBs would be an important opportunity for dialysis providers to re-
duce patients’ treatment costs under Medicare’s Prospective Payment System.
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OBJECTIVES: DKD is the primary cause of ESRD in the US, with 45% of ESRD
associated with diabetes. A cost-effectiveness model was created to evaluate the
long-term costs and benefits of a therapeutic intervention that slows the progress
to ESRD in DKD patients.METHODS: The model is a Monte Carlo microsimulation
of a semi-Markov structure with a lifetime patient perspective. Kidney disease is
modeled as normal, Stages 1 through 5, and ESRD. Proteinuria is modeled as none,
microalbuminuria, andmacroalbuminuria. Themodel incorporates cardiovascular
disease (CVD) events and mortality along with non-CVD mortality. Modeled costs
are therapy costs, regression-equation supplied annual medical costs, and ESRD
costs. Analyses were performed for diabetic males receiving ACEi or ARB therapy,
age 60, macroalbuminuria, and estimated glomerular filtration rates (eGFR) of 30
(Stage 3/4 breakpoint) and 40 (Stage 3b) mL/min/1.73m2. The intervention was
modeled as a chronic pharmaceutical therapy to be administered through kidney
disease Stage 4. We assume this confers a 28% reduction in annual eGFR degrada-
tion; this is in addition to the base case ARB-attributed reduction in eGFR degrada-
tion. Separate economic analyses were performed for annual intervention costs of
$2500 and $7500. RESULTS: Compared with SOC (i.e., ACEi or ARB treatment), and
respectively in patients at eGFRs of 30 and 40, the intervention increased QALYs
(0.29, 0.51) and life years (0.30, 0.66) and also resulted in fewer patients
reaching ESRD (-74/1,000; -104/1,000). For the intervention cost of $2500, cost sav-
ings were realized for both eGFR cohorts. For the $7,500 cost, cost-per-QALY ICERs
were calculated to be $79,965 for the eGFR 30 and $75,052 for the eGFR 40 cohorts.
CONCLUSIONS: Use of an effective therapeutic intervention to slow progression to
ESRD in high risk DKD patients can result in medical benefits (i.e., ESRD cases
avoided) and can be cost-effective or even cost saving.
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OBJECTIVES: To determine the cost-effectiveness of pharmacologic treatments for
overactive bladder.METHODS:A decisionmodel was constructed based on studies
of effectiveness, adverse consequences, comorbid conditions, and medical costs
for the treatment of overactive bladder. The model was based on a previously
published cost-effectiveness model. The 3 month model classifies patients to 1 of
three states after treatments including: 1) complete continence; 2) treatment fail-
ure; and 3) discontinuation of treatment. Estimates of complete continence were
obtained from trials involving products on the US market as of February 2011.
These products included darifenacin, fesoterodine, oxybutynin immediate release
(IR), oxybutynin extended release (ER), oxybutynin topical gel, oxybutynin trans-
dermal patch, solifenacin, tolterodine IR, tolterodine ER, trospium IR, and trospium
ER. A systematic search of MEDLINE and Embase was conducted to identify rele-
vant studies. Costs were derived from the literature and updated to 2011 values
using themedical components of the consumer price index. Medication costs were
based on wholesale acquisition cost. Probabilistic sensitivity analysis was con-
ducted using a Monte Carlo simulation. RESULTS: A total of 51 studies were iden-
tified, of which 11 studies reported complete continence rates. Complete conti-
nence rates ranged from 19.0% for darifenacin to 51.0% for solifenacin. The lowest
cost treatment was oxybutynin IR ($752 per patient) and the highest cost was
trospium IR ($1,223 per patient). The product with the lowest ICER relative to oxy-
butynin was solifenacin at $1,405 per additional continent patient. The cost-effec-
tiveness acceptability curve indicated oxybutynin IR was most cost-effective with
willingness-to-pay (WTP) values less than $10,000, and solifenacin was most cost-
effective at higher WTP values. CONCLUSIONS: Compared with generic oxybu-
tynin IR, only solifenacinwasmore cost-effective and had an ICER below $1,500 per
successfully treated patient. Only oxybutynin IR and solifenacin had a non-zero
probability of being cost-effective as compared to other therapies.
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OBJECTIVES: Pharmacists successfully manage patients with anemia and chronic
kidney disease (CKD), but these programs’ cost-effectiveness is unknown. This
analysis examines the cost-effectiveness of pharmacist-managed erythropoiesis-
stimulating agents (ESAs) clinics compared to usual physician-based care in pa-
tients with non-dialysis (ND) CKD. METHODS: A Markov model estimated the in-
cremental cost-effectiveness of pharmacist-managed ESA clinics compared with
usual care in outpatients receiving ESAs for ND-CKD at ten VA Medical Centers
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